REFLAB ApS: Financial statements 2013
CVR: 15322586
Source: annual report 2013, Danish Business Authority
01/01/2013 – 31/12/2013
REFLAB ApS (CVR 15322586) has filed annual accounts for 2013. In 2013, the company reported a gross profit of DKK 3,659,419 and a net result of DKK 98,128 compared with DKK -64,717 the year before. That is an increase of 44.7% compared with the year before. Equity in the 2013 report amounted to DKK 2,780,927. The solvency ratio was 74.9%.
- Gross Profit
- DKK 3,659,419
- Profit/Loss
- DKK 98,128
- Equity
- DKK 2,780,927
- Total Assets
- DKK 3,712,207
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2013 | - | 3.7 mio. | 98 t. | 2.8 mio. | - |
| 2012 | - | 2.5 mio. | -65 t. | 2.7 mio. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2013
REFLAB ApS has published its annual report for 2012. Gross profit came to DKK 2,528,583, and the net result was DKK -64,717.
About REFLAB ApS
REFLAB ApS is a Danish company of the type Anpartsselskab based in Hvidovre, founded in 1991. The company is registered under the industry Traditionelle, komplementære og alternative behandlingsformer. The company was previously named REFERENCELABORATORIET ApS. The management consists of Gert Pynt Andersen and Katrine Baumann Markussen. The company is owned by R-Biopharm AG. The company has 7 employees (2018). In 2025, the company reported a gross profit of DKK 4,582,184 and a net result of DKK -1,792,430 compared with DKK 652,577 the year before. Equity in the 2025 report amounted to DKK -635,048.